-1753896080231.webp&w=3840&q=75)
2025 NOSCM | MDS and Secondary AML Management in 2025
Overview
Dr. Rami Komrokji discussed MDS and secondary AML in 2025, noting 50,000 new MDS cases yearly and 1/3 progressing to AML. Key factors include CHIP and CCUS. Luspatercept is standard for RS+ MDS; telestat for lower-risk. Transplant is the only cure for high-risk MDS; hypomethylating agents offer limited benefit.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Rami Komrokji, MD
Date of Release
July 30th, 2025
-1753896006195.webp&w=3840&q=75)
-1753895830833.webp&w=3840&q=75)